Date | Title | Description | Source |
26.02.2023 | Blueprint Medicines Presents Registrational Data from PIONEE... | -- AYVAKIT achieved a statistically significant and clinically meaningful improvement in total sympt... | einpresswi... |
09.01.2023 | Healthcare Hires of Note | ProofPilot, a digital protocol automation platform for clinical trials, has added Bernadette Tosti t... | medcitynew... |
14.10.2022 | Taking Charge of a Cancer Diagnosis With Biomarker Testing | (BPT) - David was in his thirties and living a healthy life when doctors discovered a cancerous mass... | salamancap... |
02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cockta... | a16z.com/2... |
10.06.2022 | Blueprint Medicines slips as it changes endpoint for tri... | Blueprint is forging ahead on its slow crawl to broaden its market for Ayvakit.
Having nabbe... | endpts.com... |
28.01.2022 | Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positiv... | CAMBRIDGE, Mass., Jan. 28, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today... | marketscre... |
29.11.2021 | Blueprint Medicines : to Expand Precision Therapy Leadership... | Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition
of Lengo... | marketscre... |
28.10.2021 | Blueprint Medicines Reports Third Quarter 2021 Financial Res... | Blueprint Medicines Reports Third Quarter 2021 Financial Results
-- Strong AYVAKIT launch in advanc... | marketscre... |
03.09.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., Sept. 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a ... | prnewswire... |
04.08.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., Aug. 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) toda... | prnewswire... |
07.07.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a p... | prnewswire... |
04.06.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) toda... | prnewswire... |
05.05.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today... | prnewswire... |
11.04.2021 | Blueprint Medicines Data Highlight Clinical Leadership in Sy... |
CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) to... | prnewswire... |
10.04.2021 | Blueprint Medicines Presents Preclinical Data Highlighting B... |
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) to... | prnewswire... |
07.04.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a ... | prnewswire... |
05.03.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., March 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a ... | prnewswire... |
03.03.2021 | Blueprint Medicines Announces EMA Validation of Type II Vari... |
CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) tod... | prnewswire... |
05.02.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a p... | prnewswire... |
11.01.2021 | Blueprint Medicines Announces R&D Leadership Transitions |
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) tod... | prnewswire... |
05.01.2021 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a p... | prnewswire... |
04.12.2020 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a p... | prnewswire... |
01.12.2020 | Blueprint Medicines Announces FDA Approval of GAVRETO™ (pral... |
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a p... | prnewswire... |
03.11.2020 | Blueprint Medicines Announces Inducement Grants Under NASDAQ... |
CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a p... | prnewswire... |
25.09.2020 | Blueprint Medicines Announces European Commission Approval o... |
CAMBRIDGE, Mass., Sept. 25, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a... | prnewswire... |
23.09.2020 | Blueprint to take cancer drug back to FDA after positive res... | Shares of Blueprint (Nasdaq: BPMC) rose 9.7% on the Nasdaq when markets opened Tuesday, from $77.40 ... | medcitynew... |
08.09.2020 | FDA green-lights second RET inhibitor, this time from Bluepr... | Shares of Blueprint fell 3.7% on the Nasdaq when markets opened Tuesday and remained down 3.5% early... | medcitynew... |
14.07.2020 | Roche pays Blueprint $675M upfront for ex-U.S. development, ... | Under the terms of the deal, Roche will pay Blueprint $675 million upfront and make an equity invest... | medcitynew... |
31.05.2020 | Blueprint gets FDA priority review for competitor to newly a... | Shares of Blueprint were down more than 4% on the Nasdaq following the news.
The company is present... | medcitynew... |
14.05.2020 | With new lung cancer data at ASCO, Blueprint Medicines nips ... | The ARROW abstract’s release closely follows the May 8 announcement that the Food and Drug Administr... | medcitynew... |
10.01.2020 | FDA approves Blueprint Medicines’ precision therapy for rare... | Shares of Blueprint were up less than 1% on the Nasdaq when markets closed Thursday.
“Ayvakit is th... | medcitynew... |
08.01.2020 | Blueprint throws down targeted therapy gauntlet with new lun... | Shares of the company were up about 1.8% on the Nasdaq following the news. The company also plans to... | medcitynew... |
28.10.2019 | FDA to split Blueprint’s cancer drug application in two | Shares of Blueprint were down about 5 percent on the NASDAQ Monday morning following the news. GIST ... | medcitynew... |
30.07.2019 | The Big Decline In This Stock Is A Gift To Investors | Despite technological advances, most of medicine is still stubbornly one-size-fits-all. But last mon... | forbes.com... |
23.04.2017 | The March for Science: politics, puns, and plenty of numbers | Scientists are the kings and queens of data, accuracy, and facts. So in their honor, here are some f... | medcitynew... |
12.01.2017 | Why that infamous LifeSci party might soon get women on boar... | To his left is Kate Bingham, a managing partner at SV Life Sciences, who matches Rice’s enthusiasm a... | medcitynew... |
09.12.2016 | Synergy outlines upbeat PhIII data; Bluebird and Blue... | Synergy Pharmaceuticals $SGYP is following up on the late-stage success of its lead drug pl... | endpts.com... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
22.04.2016 | Why are there gnome statues decorating Blueprint Medicines? | Indeed, it’s a kinome-centric company: Developing kinase inhibitors – similar to the blockbuster can... | medcitynew... |
03.12.2015 | Announcing the 2015 50 on Fire Winners | Tonight we unveiled the 2015 50 on Fire winners during our annual 50 on Fire celebration. These 50 w... | bizjournal... |
21.11.2014 | Personalized cancer drugmaker Blueprint Medicines rakes in $... | As with nearly all Third Rock-founded startups, Blueprint touts itself less as a biotech working on ... | medcitynew... |
14.11.2014 | Blueprint Medicines Secures $50M in Series C |
CAMBRIDGE, MA, Leader in discovering and developing highly selective kinase inhibitors for genomic... | vcnewsdail... |
12.11.2014 | Blueprint Medicines Completes $50M Series C Financing | Blueprint Medicines, a Cambridge, MA-based developer of selective kinase inhibitors for genomically ... | finsmes.co... |
08.01.2014 | Blueprint Medicines Completes $25M Series B Financing | Blueprint Medicines, a Cambridge, MA-based oncology company, completed a $25m Series B financing.
T... | finsmes.co... |
08.01.2014 | Blueprint Medicines Announces $25M Series B |
CAMBRIDGE, MA, Blueprint Medicines today announced the completion of a $25 million Series B financ... | vcnewsdail... |
08.10.2013 | Horizon Discovery and Blueprint Medicines enter oncology res... | Horizon Discovery and Blueprint Medicines enter oncology research service agreement
08-10-2013
Hor... | cambridgen... |
14.06.2012 | Venture firm launches rare blood disorder therapeutics devel... | Among the company’s founders are three scientific researchers from University of California, San Fra... | medcitynew... |
24.05.2012 | Blueprint Medicines Adds Fidelity Biosciences | Blueprint Medicines, a Cambridge, MA-based developer of personalized cancer therapies, announced Fid... | finsmes.co... |
31.01.2012 | FDA-approved cancer drug gets revised label, better results ... | The cancer drug made the cover of Time magazine in 2001 around the time it was first approved by the... | medcitynew... |
13.04.2011 | Google-ITA Acquisition Advances, Nano Terra Buys Surface Log... | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
We saw acquisitions in the life sc... | xconomy.co... |
11.04.2011 | Blueprint Medicines Closes $40M Series A Financing | Blueprint Medicines, a Boston, MA-based developer of personalized cancer therapies, closed a $40m Se... | finsmes.co... |
- | FDA-approved cancer drug gets revised label, better results ... | The U.S. Food and Drug Administration has approved a revised label for cancer drug Gleevec following... | medcitynew... |
- | Venture firm launches rare blood disorder therapeutics devel... | Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic bl... | medcitynew... |
- | FDA approves Blueprint Medicines’ precision therapy for rare... | The Food and Drug Administration has approved the first ever drug for a rare subset of a type of gas... | medcitynew... |
- | FDA to split Blueprint’s cancer drug application in two | The Food and Drug Administration will review a biotech company’s approval application for a cancer d... | medcitynew... |
- | Blueprint throws down targeted therapy gauntlet with new lun... | A company developing targeted therapies for cancers expects to complete submission of data for one o... | medcitynew... |
- | The March for Science: politics, puns, and plenty of numbers | Scientists are the kings and queens of data, accuracy, and facts. So in their honor, here are some f... | medcitynew... |
- | Blueprint to take cancer drug back to FDA after positive res... | A drug already approved for a form of sarcoma that affects the digestive system has also shown effic... | medcitynew... |
- | FDA green-lights second RET inhibitor, this time from Bluepr... | The Food and Drug Administration has approved the second drug that targets a certain genetic abnorma... | medcitynew... |
- | Why are there gnome statues decorating Blueprint Medicines? | Blueprint Medicines has captured the magic and whimsy of biotechnology: It’s got about a dozen or so... | medcitynew... |
- | Roche pays Blueprint $675M upfront for ex-U.S. development, ... | Swiss drugmaker Roche has signed an agreement potentially worth more than $1.7 billion focused on an... | medcitynew... |
- | Blueprint gets FDA priority review for competitor to newly a... | Eli Lilly may have won the first-ever Food and Drug Administration approval for a drug that targets ... | medcitynew... |
- | Why that infamous LifeSci party might soon get women on boar... | It’s 7:15 a.m on the final day of the J.P. Morgan Healthcare Conference and Mike Rice, a founding pa... | medcitynew... |
- | With new lung cancer data at ASCO, Blueprint Medicines nips ... | A drug from Eli Lilly that targets rare mutations in lung and thyroid cancers has had Food and Drug ... | medcitynew... |
- | Precision medicine: from targeted therapies to advancing out... | Over the past decade, precision medicine has garnered significant attention from the oncology commun... | statnews.c... |
- | Personalized cancer drugmaker Blueprint Medicines rakes in $... | Blueprint Medicines recently announced a $50 million Series C round, meant to advance its two lead c... | medcitynew... |